NuSep tries NxGen
Thursday, 02 October, 2008
Bioseparations company NuSep [ASX: NSP] has reached a binding agreement to acquire NxGen Pharmaceuticals for $25 million.
Pending shareholder approval, NuSep will acquire all of NxGen in exchange for 294 million NuSep shares valued at 8.5c each.
This represents 87.5 per cent of NuSep's expanded capital and 10 times NxGen's net profit forecast for this financial year.
NxGen is a custom pharmaceuticals manufacturer and formulator, with products including an erectile dysfunction nasal spray it makes for a medical clinic.
1500 Queensland women to help develop ovarian cancer screening test
Postmenopausal women between the ages of 50 and 74 with intact ovaries, and no prior history of...
A neuroscientist and biochemist's antiviral lightbulb moment
While studying how certain processes work inside the human brain, an Australian scientist...
Antimicrobial resistance in children rises globally — 100K+ samples reveal
Spanning 82 countries, there was an increase in every region between 2004 and 2022, with the...
